Sensile Medical, Sanofi and Verily (formerly Google Life Sciences) are collaborating on development and commercialization of a connected insulin patch pump.
The alliance will leverage Sanofi's expertise in patient-centered diabetes solutions and insulins, Sensile Medical’s leadership in developing micro-pump technologies for medical use, and Verily’s experience in micro-electronic integration and digital healthcare technology.
“Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type 2 diabetes, as well as by those with Type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical.
Sensile Medical Ltd. is a globally leading Swiss medical technology company in the field of Large Volume Injectors. In close corporation with pharma and biotech companies, the company develops devices for liquid drug delivery. The core of their system is the patented SenseCore technology. The micro pump is cost-efficient to produce and very accurate in dosage.
(Press release)
Picture: Sensile Medical
0Comments
More news about
Company profiles on startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines